Astal Laboratories Ltd

Despite a broader market rally, Astal Laboratories Ltd has plunged to a fresh 52-week low of Rs 66 on 30 Mar 2026, marking a notable divergence from the general market trend.

Despite a broader market rally, Astal Laboratories Ltd has plunged to a fresh 52-week low of Rs 68.36 on 24 Mar 2026, marking a sharp divergence from the Sensex’s modest gains. The stock’s recent volatility and sustained downward momentum raise questions about the underlying factors driving this sell-off.

A sharp decline in Astal Laboratories Ltd shares has pushed the stock to a fresh 52-week low of Rs 69.01 on 23 Mar 2026, marking a significant 33% drop from its 52-week high of Rs 103.20. This downturn comes amid broader market weakness, but the stock’s underperformance relative to its sector and benchmark indices highlights company-specific pressures.

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, touched a fresh 52-week low of Rs.69.84 today, marking a significant decline amid broader market weakness and sectoral underperformance. The stock’s recent price action reflects ongoing pressures despite some positive financial metrics reported over the past year.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has touched a new 52-week low of Rs.70 today, marking a significant price level for the stock amid a mixed market environment.

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 March 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Astal Laboratories Ltd, a player in the Trading & Distributors sector, recorded a fresh 52-week low today at Rs.70.1, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock’s recent performance reflects a continuation of downward momentum, with notable implications for its valuation and comparative market standing.

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astal Laboratories Ltd., a micro-cap pharmaceutical intermediates and bulk drugs manufacturer, reported net profit of ₹2.36 crores for Q3 FY26 (October-December 2025), reflecting an 8.53% decline quarter-on-quarter but a modest 5.22% decline year-on-year. Despite impressive top-line expansion, the company's profitability metrics reveal a concerning deterioration in operational efficiency that has sent the stock into bearish territory, trading at ₹77.60 as of February 17, 2026—down 24.81% from its 52-week high of ₹103.20.

Astal Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting notable improvements in its quality metrics and financial trends despite valuation concerns and recent price weakness. The revised assessment follows a comprehensive review of four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Astal Laboratories Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While key metrics such as return on equity (ROE) and return on capital employed (ROCE) remain modest, improvements in sales and earnings growth alongside low debt levels have contributed to this upgrade. However, investors should weigh these positives against the company’s middling profitability ratios and recent share price underperformance relative to the Sensex.

Astal Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Astal Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 January 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.